CORDIS
EU research results

CORDIS

English EN

European Training Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent Inherited Blinding Disorder

Project information

Grant agreement ID: 813490

Status

Ongoing project

  • Start date

    1 October 2018

  • End date

    30 September 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 776 714,28

  • EU contribution

    € 3 776 714,28

Coordinated by:

UNIVERSITEIT GENT

Belgium

Objective

StarT will create an interdisciplinary and intersectorial European training network focusing on different aspects of autosomal recessive Stargardt disease (STGD1), a frequent inherited blinding disorder that affects an estimated 925,000 persons worldwide. StarT research aims to uncover the regulation of its disease gene ABCA4 and its missing heritability, in order to develop novel treatments. StarT training will give young researchers unparalleled training opportunities in outstanding vision research groups with unique expertise in omics technologies, bio-informatics, stem cell biology, animal models of disease, and therapeutics, providing each ESR with the necessary competences in state-of-the-art academic and industrial research.
STGD1 is due to ABCA4 mutations, however up to 35% of STGD1 cases carries one or no ABCA4 coding mutation. New unconventional classes of ABCA4 mutations were recently discovered by us, the significance of which largely remains elusive. In order to understand the mechanisms triggered by these missing ABCA4 mutations and to design new therapies for STGD1 cases, challenging research questions will be addressed by the integration of unique skills from this network.
Early-Stage Researchers will perform cutting edge research using innovative and interdisciplinary approaches: (functional) genomics and transcriptomics, bio-informatics, CRISPR/Cas9 genome editing, generation of stem cell and animal disease models and design of new treatments. The training objectives will be met through academic and industrial training-by-research via individual research projects, secondments, and network-wide training sessions.

Coordinator

UNIVERSITEIT GENT

Address

Sint Pietersnieuwstraat 25
9000 Gent

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 768 960

Participants (9)

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 531 239,76

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 252 788,40

FONDAZIONE TELETHON

Italy

EU Contribution

€ 522 999,36

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 303 172,56

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 250 904,88

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 274 684,32

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 303 172,56

NEWCELLS BIOTECH LIMITED

United Kingdom

EU Contribution

€ 303 172,56

PROQR THERAPEUTICS NV

Netherlands

EU Contribution

€ 265 619,88

Partners (5)

EUROPEAN VISION INSTITUTE - EEIG

Belgium

F. HOFFMANN-LA ROCHE AG

Switzerland

20MED THERAPEUTICS BV

Netherlands

Fighting Blindness

Ireland

INTERNATIONAL RETINITIS PIGMENTOSA ASSOCIATION

Switzerland

Project information

Grant agreement ID: 813490

Status

Ongoing project

  • Start date

    1 October 2018

  • End date

    30 September 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 776 714,28

  • EU contribution

    € 3 776 714,28

Coordinated by:

UNIVERSITEIT GENT

Belgium